^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Glioblastoma |
| Drug: | ABM-1310 (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ABM Therapeutics' ABM-1310 Granted Fast Track Designation by the FDA Following Orphan Drug Designation
Published date:
09/26/2023
Excerpt:
ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.
